AbbVie’s Skyrizi hits the spot in refractory psoriasis

New data with AbbVie’s IL-23 inhibitor Skyrizi suggests it can alleviate symptoms in psoriasis patients who don’t respond well to other biologics for the skin disease, inc

Lilly raises 2020 earnings forecast on pandemic stockpiling

Novartis’ Cosentyx didn’t EXCEED Humira in psoriatic arthrit...

Lilly dips as biomed chief Christi Shaw heads to Gilead

Lilly’s Taltz scrapes win against Humira in psoriatic arthri...

Eli Lilly’s Taltz has beaten AbbVie’s blockbuster Humira in a psoriatic arthritis study involving patients who hadn’t been treated before with a disease-modifying drug, but only just.